Alkermes (ALKS) Jefferies 2024 Global Healthcare Conference summary

Key clinical insights and data updates

• Recent SLEEP conference data established orexin 2 receptor agonists as effective in driving wakefulness for narcolepsy, with robust efficacy and strong patient-reported outcomes, especially in NT1 patients.

• No evidence of tachyphylaxis or significant tolerability issues over eight weeks; insomnia side effects largely attenuated after five days, and dropouts were minimal.

• Competitive landscape is evolving, with Takeda's drug showing efficacy but not perfection, opening opportunities for differentiation.

• Upcoming data for NT2 and idiopathic hypersomnia (IH) patients will be presented in September, expanding the clinical picture.

• Sleep architecture effects are anticipated but not yet fully analyzed; patient experience and wakefulness remain primary endpoints.

Dosing, titration, and safety considerations

• Dose-dependent increases in efficacy and side effects observed, with higher doses initially causing more insomnia that diminishes over time.

• Phase II studies use fixed dosing (4, 6, 8 mg for NT1; 10, 14, 18 mg for NT2) to assess tolerability, with a later extension phase allowing dose adjustment.

• Visual disturbances were rare, mild, and transient, with no dose-limiting toxicity or impact on driving; further real-world data will clarify their significance.

• No significant blood pressure excursions observed; ongoing studies will further assess long-term safety and side effect profiles.

Commercial and strategic outlook

• Lybalvi launch is progressing linearly, with gradual uptake and payer negotiations ongoing; a major commercial contract was recently secured, with more expected in 2024.

• Payer dynamics remain challenging, with increasing demands for discounts, but broader access is anticipated as contracts are finalized.

• Orexin program is advancing rapidly, with narcolepsy as the core opportunity and potential for broader indications; current pace matches or exceeds what a larger pharma could achieve.

• Strategic partnerships or broader commercialization may be considered as more data, especially from longer-duration phase II studies, become available.